Ask AI
Advances and Challenges in RR B ALL

CME

Clinical Advances in Immune-Engager Therapies for the Treatment of Relapsed/Refractory B-ALL

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: April 29, 2026

Expiration: October 28, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Ibrahim Aldoss, MD, discusses recent advances in immunotherapies, including bispecific T-cell engagers and CAR T-cell therapies, and emerging strategies to address resistance and improve outcomes of patients relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary. 

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with B-ALL do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

Surovatamig is a bispecific antibody in a phase I/II trial that enrolled patients with B-ALL and who were positive for which of the following biomarkers?

Which of the following findings was recently reported from the phase I/II SYRUS trial of surovatamig (AZD0486) in patients with R/R B-ALL?

A patient with B-ALL being treated with a T-cell–directed therapy experiences grade 4 CRS. What is the recommended CRS management strategy for this patient?